Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
NCT07711418Phase 3Recruiting
- Sponsor
- Nektar Therapeutics
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 3 trial of rezpegaldesleukin in atopic dermatitis (AD), sponsored by Nektar Therapeutics. Started Aug 2026; status: recruiting.
02
Drugs
rezpegaldesleukin
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07711418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07711418.